Cancer detection often feels limited, with only five types of cancer having standard screening tests. Now, with TruCheck, we have the chance to revolutionise cancer detection. Integrating TruCheck into your routine health check-ups elevates your ability to spot cancer early, giving you the advantage of early treatment.
With a single blood test, our innovative screening looks for a specific marker found in 70 types of cancer that might otherwise stay hidden. If our test identifies a potential cancer signal, our technology can pinpoint the tissue type or organ where the signal originates with 88% precision. This crucial insight guides your next steps, helping your healthcare professional determine the appropriate diagnostic follow-ups, which could include additional lab work or imaging to confirm a cancer diagnosis.
*In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with a “Cancer Signal Detected” test result.
Cancer is a disease that doesn’t discriminate, but age is undoubtedly a significant risk factor. Adults over the age of 50 are 13 times more likely to develop cancer compared to individuals under 50. Cancer risk escalates with age for everyone, irrespective of their family history—only 5% to 10% of cancers are inherited.
TruCheck is designed primarily for adults who have a heightened risk of cancer, such as those aged 40 or older.
TruCheck is not recommended for those who are pregnant, under 40 years old, or those currently undergoing active cancer treatment. Early detection can make all the difference. Trust TruCheck to be a part of your proactive health journey.
Around 70% of cancer deaths* are caused by cancers without recommended screenings.7
In a clinical study, TruCheck approximately doubled the number of cancers detected with recommended screening.3
*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
Please fill in the following form and we’ll get back to you. Our typical response time is 24 hours. You can also contact us at +44 20 4530 7605 or help@cancerscanuk.co.uk
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
